Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2008 | Review Article

ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine

Authors: Ferid Haddad, Ludovic Ferrer, Arnaud Guertin, Thomas Carlier, Nathalie Michel, Jacques Barbet, Jean-François Chatal

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2008

Abstract

Purpose

This study was aimed at establishing a list of radionuclides of interest for nuclear medicine that can be produced in a high-intensity and high-energy cyclotron.

Methods

We have considered both therapeutic and positron emission tomography radionuclides that can be produced using a high-energy and a high-intensity cyclotron such as ARRONAX, which will be operating in Nantes (France) by the end of 2008. Novel radionuclides or radionuclides of current limited availability have been selected according to the following criteria: emission of positrons, low-energy beta or alpha particles, stable or short half-life daughters, half-life between 3 h and 10 days or generator-produced, favourable dosimetry, production from stable isotopes with reasonable cross sections.

Results

Three radionuclides appear well suited to targeted radionuclide therapy using beta (⁶⁷Cu, ⁴⁷Sc) or alpha (²¹¹At) particles. Positron emitters allowing dosimetry studies prior to radionuclide therapy (⁶⁴Cu, ¹²⁴I, ⁴⁴Sc), or that can be generator-produced (⁸²Rb, ⁶⁸Ga) or providing the opportunity of a new imaging modality (⁴⁴Sc) are considered to have a great interest at short term whereas ⁸⁶Y, ⁵²Fe, ⁵⁵Co, ⁷⁶Br or ⁸⁹Zr are considered to have a potential interest at middle term.

Conclusions

Several radionuclides not currently used in routine nuclear medicine or not available in sufficient amount for clinical research have been selected for future production. High-energy, high-intensity cyclotrons are necessary to produce some of the selected radionuclides and make possible future clinical developments in nuclear medicine. Associated with appropriate carriers, these radionuclides will respond to a maximum of unmet clinical needs.

Pentlow KS, Graham MC, Lambrecht RM, Cheung NK, Larson SM. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys 1991;18(3):357–66. May–Jun.PubMedCrossRef

DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumour regression in patients with lymphoma. J Nucl Med 1999;40(2):302–10, Feb.PubMed

Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for ¹³¹I thyroid cancer therapy using ¹²⁴I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366–72. Aug.PubMed

Barbet J, Chatal JF, Gauche F, Martino J. Which radionuclides will nuclear oncology need tomorrow? Eur J Nucl Med Mol Imaging 2006;33(6):627–30, Jun.PubMedCrossRef

Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059.PubMed

Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005;46:164S–71S.PubMed

Lee FT, Scott AM. Immuno-PET for tumor targeting. J Nucl Med 2003;44:1282–3.PubMed

Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006;50(4):248–64, Dec.PubMed

de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003;30(3):463–9, Mar.PubMed

10.

Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24(5):823–34. Feb 10.PubMedCrossRef

11.

Kolsky KL, Joshi V, Mausner LF, Srivastava SC. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Appl Radiat Isot 1998;49:1541–49.PubMedCrossRef

12.

DeNardo GL, DeNardo SJ, Kukis DL, O'Donnell RT, Shen S, Goldstein DS, et al. Maximum tolerated dose of 67-Cu-2IT-BAT-LYM1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anti Cancer Res 1998;18:2779–88.

13.

Robinson S, Julyan PJ, Hastings DL, Zweit J. Performance of a block detector PET scanner in imaging non-pure positron emitters—modelling and experimental validation with ¹²⁴I. Phys Med Biol 2004;49:5505.PubMedCrossRef

14.

Williams HA, Robinson S, Julyan P, Zweit J, Hastings D. A comparison of PET imaging characteristics of various copper radioisotopes. Eur J Nucl Med 2005;32:1473.CrossRef

15.

Zimmermann K, Grönberg J, Honer M, Ametamey S, Schubiger PA, Novak-Hofer I. Targeting of renal carcinoma with ^67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl Med Biol 2003;30:417.PubMedCrossRef

16.

Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, Connett JM, Zinn ZR, et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995;36:1818.PubMed

17.

Shen S, DeNardo GL, DeNardo SJ, Salako Q, Morris G, Banks D, et al. Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy. J Nucl Med 1996;37:146.PubMed

18.

Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998;25:788.PubMedCrossRef

19.

Laforest R, Dehashti F, Lewis JS, Schwarz SW. Dosimetry of ^60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med 2005;32:764.CrossRef

20.

Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand ⁶⁸Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751.PubMedCrossRef

21.

Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67/gallium-68-[DFO]-octreotide—a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35:317.PubMed

22.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of ⁶⁸Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46(Suppl):763.PubMed

23.

Klivonyi G, Schuhmacher J, Patzelt E, Hauser H, Matys R, Moock M, et al. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J Nucl Med 1998;39:1769.

24.

Schuhmacher J, Kaul S, Klivonyi G, Junkermann H, Magener A, Henze M, et al. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res 2001;61:3712.PubMed

25.

Sanchez-Crespo A, Andreo P, Larsson SA. Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging 2004;31:44.PubMedCrossRef

26.

Maecke HR, Hofmann M, Haberkorn U. ⁶⁸Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46(Suppl):172S.PubMed

27.

Shea MJ, Wilson RA, deLandsheere CM, Deanfield JE, Watson IA, Kensett MJ, et al. Use of short and long-lived rubidium tracers for the study of transient ischemia. J Nucl Med 1987;28:989.PubMed

28.

Anonymous. The strontium-82/rubidium-82 generator. Int J Rad Appl Instrum 1987;38(3):171–239.

29.

Erdi Y, Macapinlac H, Larson S, Erdi A, Yeung H, Furhang E, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging 1999;2:41.PubMedCrossRef

30.

Eschmann MS, Reischl G, Bilger K, Kupferschleger J, Thelen MH, Dohmen BM, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002;29:760–7.PubMedCrossRef

31.

Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005;65:622.PubMed

32.

Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, et al. ¹²⁴I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962.PubMed

33.

Lee FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O'Keefe GJ, et al. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using ¹²⁴I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med 2001;42:764.PubMed

34.

Keen HG, Dekker BA, Disley L, Hastings D, Lyons S, Reader AJ, et al. Imaging apoptosis in vivo using ¹²⁴I-annexin V and PET. Nucl Med Biol 2005;32:395.PubMedCrossRef

35.

Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005;65:1471.PubMedCrossRef

36.

Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem 2004;12:3421.PubMedCrossRef

37.

IAEA. Optimization of production and quality control of therapeutic radionuclides and radiopharmaceuticals. IAEA-TECDOC-1114 1999. Vienna: IAEA; 1999.

38.

Sachdev DR, Yaffe L. Isomer ratios for the 44Ca(p,n)44m,gSc and 85Rb(p,n)85m,gSr reactions. Can J Phys 1969;47:1667.

39.

Kurfess JD, Phlips BF (2001) Coincident Compton nuclear medical imager. In: Proceedings of the IEEE Nuclear Science Symposium conference, San Diego, California.

40.

Kurfess JD, Johnson WN, Kroeger RA, Phlips BF, Wulf EA. Timing methods for depth determination in germanium strip detectors. Nucl Instr Meth A 2003;505:178.CrossRef

41.

Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971.PubMed

42.

Rosch F, Herzog H, Stolz B, Brockmann J, Kohle M, Muhlensiepen H, et al. Uptake kinetics of the somatostatin receptor ligand ⁸⁶YDOTA-DPhe1- Tyr3-octreotide (86YSMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med 1999;26:358.PubMedCrossRef

43.

Lundqvist H, Lubberink M, Tolmachev V, Lovqvist A, Sundin A, Beshara S, et al. Positron emission tomography and radioimmunotargeting general aspects. Acta Oncol 1999;38:335.PubMedCrossRef

44.

Wester HJ, Brockmann J, Rosch F, Wutz W, Herzog H, Smith-Jones P, et al. PET-pharmacokinetics of ¹⁸F-octreotide: a comparison with ⁶⁷Ga-DFO- and ⁸⁶Y-DTPA-octreotide. Nucl Med Biol 1997;24:275.PubMedCrossRef

45.

Yoo J, Tang L, Perkins TA, Rowland DJ, Laforest R, Lewis, et al. Preparation of high specific activity (86)Y using a small biomedical cyclotron. Nucl Med Biol 2005;32:891.PubMedCrossRef

46.

Buchholz HG, Herzog H, Förster GJ, Reber H, Nickel O, Rösch F, et al. PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction. Eur J Nucl Med Mol Imaging 2003;30:716.PubMed

47.

Walrand S, Jamar F, Mathieu L, De Camps J, Lonneux M, Sibomana M, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003;30:354.PubMed

48.

Beattie BJ, Finn RD, Rowland DJ, Pentlow KS. Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays. Med Phys 2003;30:2410.PubMedCrossRef

49.

Kull T, Ruckgaber J, Weller R, Reske S, Glatting G. Quantitative imaging of yttrium-86 PET with the ECAT EXACT HR+ in 2D mode. Cancer Biother Radiopharm 2004;19:482.PubMed

50.

Herzog H, Rosch F, Stocklin G, Lueders C, Qaim SM, Feinendegen LE. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J Nucl Med 1993;34:2222.PubMed

51.

Forster GJ, Engelbach MJ, Brockmann JJ, Reber HJ, Buchholz HG, Macke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med 2001;28:1743.PubMedCrossRef

52.

De Reuck J, Santens P, Strijckmans K, Lemahieu I, Lemahieu I. Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes. J Neurol Sci 2001;193:1.PubMedCrossRef

53.

Stevens H, Jansen HM, De Reuck J, Lemmerling M, Strijckmans K, Goethals P, et al. ⁵⁵Co-PET in stroke: relation to bloodflow, oxygen metabolism and gadolinium-MRI. J Neurol Sci 1999;171:11.PubMedCrossRef

54.

Jansen HM, Dierckx RA, Hew JM, Paans AM, Minderhoud JM, Korf J. Positron emission tomography in primary brain tumours using cobalt-55. Nucl Med Commun 1997;18:734.PubMedCrossRef

55.

Ellis BL, Sharma HL. Co, Fe and Ga chelates for cell labelling: a potential use in PET imaging? Nucl Med Commun 1999;20:1017.PubMedCrossRef

56.

Karanikas G, Schmaljohann J, Rodrigues M, Chehne F, Granegger S, Sinzinger H. Examination of co-complexes for radiolabeling of platelets in positron emission tomographic studies. Thromb Res 1999;94:111.PubMedCrossRef

57.

Jansen HM, Knollema S, van der Duin LV, Willemsen AT, Wiersma A, Franssen EJ, et al. Pharmacokinetics and dosimetry of cobalt-55 and cobalt-57. J Nucl Med 1996;37:2082.PubMed

58.

Zaman MR, Spellerberg S, Qaim SM. Production of ⁵⁵Co via the ⁵⁴Fe(d,n)-process and excitation functions of ⁵⁴Fe(d,t)⁵³Fe and ⁵⁴Fe(d,α)^52mMn reactions from threshold up to 13.8 MeV. Radiochim Acta 2003;91:105.CrossRef

59.

Francois PE, Szur L. Use of iron-52 as a radioactive tracer. Nature 1958;182:1665.PubMedCrossRef

60.

Anger HO, Vandyke DC. Human bone marrow distribution shown in vivo by iron-52 and the positron scintillation camera. Science 1964;144:1587.PubMedCrossRef

61.

Silvester DJ, Sugden J. Production of carrier-free iron-52 for medical use. Nature 1966;210:1282.PubMedCrossRef

62.

Bailey DL, Young H, Bloomfield PM, Meikle SR, Glass D, Myers MJ, et al. ECAT ART—a continuously rotating PET camera: performance characteristics, initial clinical studies, and installation considerations in a nuclear medicine department. Eur J Nucl Med 1997;24:6.PubMedCrossRef

63.

Zweit J, Downey S, Sharma H. A method for the production of iron-52 with a very low iron-55 contamination. Int J Rad Appl Instrum 1988;39:1197–201.CrossRef

64.

Atcher RW, Friedman AM, Huizenga JR, Rayudu GV, Silverstein EA, Turner DA. Manganese-52m, a new short-lived, generator-produced radionuclide: a potential tracer for positron tomography. J Nucl Med 1980;21:565.PubMed

65.

Lubberink M, Tolmachev V, Beshara S, Lundqvist H. Quantification aspects of patient studies with ⁵²Fe in positron emission tomography. Appl Radiat Isot 1999;51(6):707–15, Dec.PubMedCrossRef

66.

Sundin J, Tolmachev V, Koziorowski J, Carlsson J, Lundqvist H, Welt S, et al. High yield direct ⁷⁶Br-bromination of monoclonal antibodies using chloramine-T. Nucl Med Biol 1999;26:923.PubMedCrossRef

67.

Lovqvist A, Sundin A, Ahlstrom H, Carlsson J, Lundqvist H. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. J Nucl Med 1997;38:395–401.PubMed

68.

Lu L, Samuelsson L, Bergstrom M, Sato K, Fasth KJ, Langstrom B. Rat studies comparing ¹¹C-FMAU, ¹⁸F-FLT, and ⁷⁶Br-BFU as proliferation markers. J Nucl Med 2002;43:1688–98.PubMed

69.

Meijs WE, Haisma HJ, Klok RP, Van Gog FB, Kievit E, Pinedo HM, et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med 1997;38:112–8.PubMed

70.

Verel I, Visser GWM, Boellaard R, Boerman OC, Van Eerd J, Snow GB, et al. Quantitative ⁸⁹Zr immuno-PET for in vivo scouting of ⁹⁰Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003;44:1663.PubMed

71.

Mausner LF, Kolsky KL, Joshi V, Srivastava SC. Radionuclide development at BNL for nuclear medicine therapy. Appl Radiat Isot 1998;49:285–94.PubMedCrossRef

72.

DeNardo GL, DeNardo SJ, Meares CF, Kukis DL, Diril H, McCall MJ, et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and patients with lymphoma. Antibody Immunoconj Radiopharm 1991;4:777–85.

73.

DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ. 67-Cu versus 131-I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin’s lymphoma. Clin Cancer Res 1999;5:533–41.PubMed

74.

O’Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, et al. A clinical trial of radioimmunotherapy with 67-Cu-2IT-BATLym- 1. J Nucl Med 1999;40:2014–20.PubMed

75.

DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 1999;40:302–10.PubMed

76.

Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002;29:821–30.PubMedCrossRef

77.

McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 1998;25:1341–51.CrossRef

78.

Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted alpha-particle therapy. J Nucl Med 2005;46(Suppl 1):199S–204S.PubMed

79.

Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 2005;32:601–14.PubMedCrossRef

80.

Johnson EL, Turkington TG, Jaszczak RJ, et al. Quantitation of ²¹¹At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl Med Biol 1995;22:45–54.PubMedCrossRef

81.

Welch MJ. Potential and pitfalls of therapy with alpha-particles. J Nucl Med 2005;46:1254–5.PubMed

82.

Cherel M, Davodeau F, Kraeber-Bodere F, Chatal JF. Current status and perspectives in alpha radioimmunotherapy. Q J Nucl Med Mol Imaging 2006;50:322–9.PubMed

83.

Szelecsényi F, Steyn GF, Kovács Z, Vermeulen C, van der Meulen NP, Dolley SG, et al. Investigation of the ⁶⁶Zn(p,2pn)⁶⁴Cu and ⁶⁸Zn(p,x)⁶⁴Cu nuclear processes up to 100 MeV: production of ⁶⁴Cu. Nucl Instr and Meth B 2005;240:625.CrossRef

84.

Mausner LF, Hock JC. Target design consideration for isotope production with high intensity 200 MeV protons. Nucl Inst Meth A 1997;397:18.CrossRef

85.

Quaim SM. Nuclear data for medical applications: an overview. Radiochim Acta 2001;89:189.CrossRef

Title: ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine
Authors: Ferid Haddad
Ludovic Ferrer
Arnaud Guertin
Thomas Carlier
Nathalie Michel
Jacques Barbet
Jean-François Chatal
Publication date: 01-07-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0802-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2008

The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI

Spent Technetium-99m generator body adapted for sterilization of radioactive preparations

Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results

The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism

Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases

EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy